Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Atea Announces Update on Collaboration with Roche for AT-527

11/16/2021 | 10:17pm EST

Atea Announces Update on Collaboration with Roche for AT-527

TOKYO, November 17, 2021 --Chugai Pharmaceutical Co., Ltd.(TOKYO: 4519) announced that Atea issued a press release on its collaboration with Roche for the investigational oral COVID-19 treatment AT- 527.

Please refer to the link below for details:

Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update- strategic-collaboration

###

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 17 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2021 03:16:07 UTC.


ę Publicnow 2021
All news about CHUGAI PHARMACEUTICAL CO., LTD
01/21CHUGAI PHARMACEUTICAL : Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia..
PU
2021CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2021CHUGAI PHARMACEUTICAL : Signs Joint Research Agreement with NCC for Asian International Co..
PU
2021Launch of Chugai's New TV Commercial 'Protect the Ordinary Days People Cherish' Featuri..
AQ
2021CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indi..
PU
2021CHUGAI PHARMACEUTICAL : Launch of Chugai's New TV Commercial “Protect the Ordinary D..
PU
2021Chugai Pharmaceutical Co., Ltd. - Notice of Board of Director's Resolution on Applicati..
AQ
2021Chugai Obtained Highest A-Rating by CDP in Two Categories and SBT Validation for Greenh..
AQ
2021Chugai Pharmaceutical Co. - Update on the Development of Oral COVID-19 Drug Candidate A..
AQ
2021Nikkei 225 Declines 1.8% on Central Bank Outlooks
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2021 975 B 8 577 M 8 577 M
Net income 2021 292 B 2 569 M 2 569 M
Net cash 2021 461 B 4 056 M 4 056 M
P/E ratio 2021 20,7x
Yield 2021 1,87%
Capitalization 6 051 B 53 179 M 53 211 M
EV / Sales 2021 5,73x
EV / Sales 2022 5,37x
Nbr of Employees 7 555
Free-Float -
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 680,00 JPY
Average target price 4 823,85 JPY
Spread / Average Target 31,1%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-1.47%53 179
JOHNSON & JOHNSON-3.40%434 036
ROCHE HOLDING AG-4.87%319 830
PFIZER, INC.-10.60%296 303
ABBVIE INC.-2.53%233 325
ELI LILLY AND COMPANY-11.98%220 356